ATE287717T1 - Verwendung eines oestrogens zur verhütung und behandlung von ischaemischer schädigung - Google Patents

Verwendung eines oestrogens zur verhütung und behandlung von ischaemischer schädigung

Info

Publication number
ATE287717T1
ATE287717T1 AT97950607T AT97950607T ATE287717T1 AT E287717 T1 ATE287717 T1 AT E287717T1 AT 97950607 T AT97950607 T AT 97950607T AT 97950607 T AT97950607 T AT 97950607T AT E287717 T1 ATE287717 T1 AT E287717T1
Authority
AT
Austria
Prior art keywords
estrogen
prevention
treatment
ischemic injury
population
Prior art date
Application number
AT97950607T
Other languages
English (en)
Inventor
James W Simpkins
Original Assignee
Univ Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida filed Critical Univ Florida
Application granted granted Critical
Publication of ATE287717T1 publication Critical patent/ATE287717T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Physiology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT97950607T 1996-11-15 1997-11-14 Verwendung eines oestrogens zur verhütung und behandlung von ischaemischer schädigung ATE287717T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/749,703 US5877169A (en) 1993-11-05 1996-11-15 Methods of treatment of ischemic damage
PCT/US1997/020875 WO1998022113A1 (en) 1996-11-15 1997-11-14 Methods of prevention and treatment of ischemic damage

Publications (1)

Publication Number Publication Date
ATE287717T1 true ATE287717T1 (de) 2005-02-15

Family

ID=25014823

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97950607T ATE287717T1 (de) 1996-11-15 1997-11-14 Verwendung eines oestrogens zur verhütung und behandlung von ischaemischer schädigung

Country Status (8)

Country Link
US (1) US5877169A (de)
EP (1) EP0942736B1 (de)
JP (1) JP2001504488A (de)
KR (1) KR20000053321A (de)
AT (1) ATE287717T1 (de)
CA (1) CA2271273A1 (de)
DE (1) DE69732367D1 (de)
WO (1) WO1998022113A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319914B1 (en) * 1993-11-05 2001-11-20 Apollo Biopharmaceuticals, Inc. Cytoprotective effect of polycyclic phenolic compounds
US6350739B1 (en) * 1999-08-11 2002-02-26 University Of Florida Resarch Foundation, Inc. Methods of prevention and treatment of ischemic damage
US20060264357A1 (en) * 1997-04-22 2006-11-23 Zikria Bashir A Capillary membrane stabilization and reduction of tissue injury through use of biodegradable macromolecules with antioxidants and/or other chemicals
WO2000028982A2 (en) 1998-11-19 2000-05-25 The Board Of Trustees For The University Of Arkansas Increasing bone strength with selected bisphosphonates
US6339078B1 (en) * 1999-07-20 2002-01-15 University Of Florida Research Foundation, Inc. Methods of prevention and treatment of ischemic damage
US6326365B1 (en) 1999-07-20 2001-12-04 Apollo Biopharmaceutics, Inc. Methods of prevention and treatment of ischemic damage
CA2413552A1 (en) * 2000-06-27 2002-01-03 University Of Florida Research Foundation, Inc. Alkyl ether modified polycyclic compounds having a terminal phenol as cell protecting agents
GB2363983A (en) 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 7-hydroxyepiandrosterone
AU2001285076A1 (en) * 2000-08-17 2002-02-25 Apollo Biopharmaceutics Inc. Formulation for administering therapeutic lipophilic molecules
ES2287184T3 (es) * 2000-11-03 2007-12-16 Washington University Estructuras aromaticas modificadas con sustituyentes hidroxi-, que tienen actividad citoprotectora.
EP1834959B1 (de) 2000-11-03 2012-08-08 Washington University Tert-butyl-substituierte aromatische Steroide mit zytoprotektiver Wirkung
AU2002228891A1 (en) * 2000-11-17 2002-05-27 Washington University Cytoprotective estrogen derivatives
US20030216329A1 (en) * 2001-04-24 2003-11-20 Robinson Cynthia B. Composition, formulations & kit for treatment of respiratory & lung disease with dehydroepiandrosterone(s) steroid & an anti-muscarinic agent(s)
AU2002325712C1 (en) 2001-08-30 2008-07-31 Stem Cell Therapeutics Inc. Differentiation of neural stem cells and therapeutic use theeof
US20040214806A1 (en) * 2002-09-03 2004-10-28 Iok-Hou Pang Use of non-feminizing estrogens as retinoprotective agents for the treatment of glaucoma
US7488723B2 (en) 2001-09-05 2009-02-10 Alcon, Inc. Use of non-feminizing estrogens as treatment for retinal vascular diseases
AR036401A1 (es) * 2001-09-14 2004-09-08 Stem Cell Therapeutics Inc Incremento de la cantidad de celulas madre neuronales inducido por prolactina.
AU2002325710A1 (en) * 2001-09-18 2003-04-01 Stem Cell Therapeutics Inc. Effect of growth hormone and igf-1 on neural stem cells and therapeutic application
CA2468342A1 (en) * 2001-12-05 2003-06-12 Mitokor, Inc. Use of polycyclic phenolic compounds for the treatment of opthalmic diseases
ATE415387T1 (de) * 2002-05-15 2008-12-15 Genzyme Corp Verfahren zur herstellung von benzonitrilen und benzimidosäure-derivaten
EP1546198A1 (de) * 2002-07-31 2005-06-29 Stem Cell Therapeutics Inc. Verfahren zur verbesserung der proliferation, der differenzierung und des berlebens von neuralen stammzellen unter verwendung von pituitary adenylate cyclase activating polypeptide (pacap)
US20070111932A1 (en) * 2003-07-31 2007-05-17 Stem Cell Therapeutics Inc. Method of enhancing and/or inducing neuronal migration using erythropoietin
CA2556266A1 (en) * 2004-02-13 2005-08-25 Stem Cell Therapeutics Corp. Use of luteinizing hormone (lh), and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesis
EP1749017A2 (de) * 2004-05-27 2007-02-07 MIGENIX Corp. Verbindungen und verfahren für zytoprotektion
US7304073B2 (en) * 2004-08-20 2007-12-04 Wyeth Method of treating myocardial ischemia-reperfusion injury using NF-kB inhibitors
AU2006297041A1 (en) * 2005-09-27 2007-04-05 Stem Cell Therapeutics Corp. Oligodendrocyte precursor cell proliferation regulated by prolactin
JP2009530234A (ja) * 2006-03-17 2009-08-27 ステム セル セラピューティクス コーポレイション 神経変性疾患の治療のためのｌｈまたはｈｃｇ、およびｅｐｏについての投与レジメン
US20070287684A1 (en) 2006-05-22 2007-12-13 Irshad Chaudry Methods and compositions for treating trauma-hemorrhage using estrogen and derivatives thereof
US9359451B2 (en) 2012-05-15 2016-06-07 The Uab Research Foundation Methods and compositions for treating trauma-hemorrhage using estrogen and derivatives thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05178883A (ja) * 1991-09-27 1993-07-20 Oyo Seikagaku Kenkyusho カテコールエストロゲンのシクロデキストリン包接複合体及びその用途
US5587369A (en) * 1993-03-09 1996-12-24 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
DE4319096C1 (de) * 1993-06-08 1994-09-08 Kuhl Herbert Prof Dr Phil Nat Hormonales Mittel zur Vorbeugung und Behandlung arterieller Erkrankungen beim Mann
US5512557A (en) * 1993-10-07 1996-04-30 National Heart And Lung Institute Coronary heart disease treated with 17βoestradiol
AU7569194A (en) * 1993-08-20 1995-03-21 Meyer B. Jackson Method for regulating neuropeptide hormone secretion
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
DE4338314C1 (de) * 1993-11-10 1995-03-30 Jenapharm Gmbh Pharmazeutische Präparate zur Prophylaxe und Therapie radikalvermittelter Zellschädigungen
JPH08165242A (ja) * 1994-12-09 1996-06-25 Kunio Yagi 抗動脈硬化剤
DE19524937A1 (de) * 1995-07-08 1997-01-09 Jenapharm Gmbh Pharmazeutische Präparate zur Prophylaxe und Therapie radikalvermittelter Zellschädigungen und zur medikamentösen Substitution beim Mann

Also Published As

Publication number Publication date
US5877169A (en) 1999-03-02
DE69732367D1 (de) 2005-03-03
CA2271273A1 (en) 1998-05-28
JP2001504488A (ja) 2001-04-03
WO1998022113A1 (en) 1998-05-28
KR20000053321A (ko) 2000-08-25
EP0942736B1 (de) 2005-01-26
EP0942736A1 (de) 1999-09-22

Similar Documents

Publication Publication Date Title
DE69732367D1 (de) Verwendung eines oestrogens zur verhütung und behandlung von ischaemischer schädigung
DE69529577D1 (de) Prophylaktische und therapeutische behandlung von haupt sensibilisierung und -reizung
DE69720745D1 (de) Therapeutische kombinationen von rar-antagonisten und rxr-agonisten
DE69034148D1 (de) Kombinationstherapie zur Prophylaxe und/oder Behandlung von gutartiger prostatischer Hyperplasie
TR200002784T2 (tr) Tip 5 ve tip 3 17beta-Hidroksisteroid dehidrojenaz inhibitörleri ve bunların kullanımı için metodlar
ATE212546T1 (de) Behandlung von neurodegenerativen zuständen mittels nimesulide
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
DE69833971D1 (de) Verfahren zur behandlung von alzheimerschen krankheit
ATE186834T1 (de) Verwendung von wirksamen mengen von aktiven stoffen zur behandlung von mischhaut
EA200200132A1 (ru) СЕЛЕКТИВНЫЕ АНТАГОНИСТЫ РЕЦЕПТОРА iGluRДЛЯ ЛЕЧЕНИЯ МИГРЕНИ
BR9808221A (pt) Método de tratamento de tumor.
ATE541565T1 (de) Topische verwendung von muskarinischen und opioiden mitteln zur behandlung von tinnitus
ATE214272T1 (de) Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz
ATE453402T1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
DE69625682D1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
EP0992243A4 (de) Stoff für die prophylaxe oder therapie
ATE297739T1 (de) Endothelin-antagonisten zur behandlung von herzversagen
ATE293972T1 (de) Behandlung von chronischen schmerzen
DE69623316D1 (de) Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen
LV11593A (lv) Dimetikona pielietojums aizcietejumu arstesana
ATE236633T1 (de) Topische verwendung von loperamid zur behandlung mikrobieller infektionen
MX9701606A (es) Terapia de combinacion para evitar la perdida osea-progesterona y agonistas de estrogeno.
ATE271867T1 (de) Behandlung der harninkontinenz und zusammenstellung dafür
SE9301606D0 (sv) Composition for the treatment of impaired hair growth

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties